Immunovant, Inc. (IMVT)
| Market Cap | 8.13B +158.6% |
| Revenue (ttm) | n/a |
| Net Income | -505.61M |
| EPS | -2.77 |
| Shares Out | 206.40M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 727,071 |
| Open | 39.80 |
| Previous Close | 39.37 |
| Day's Range | 38.70 - 39.87 |
| 52-Week Range | 14.32 - 41.23 |
| Beta | 0.77 |
| Analysts | Buy |
| Price Target | 47.53 (+20.6%) |
| Earnings Date | Aug 6, 2026 |
About IMVT
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren’s disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Scienc... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for IMVT stock is "Buy." The 12-month stock price target is $47.53, which is an increase of 20.60% from the latest price.
News
Immunovant Proxy statement: Proxy filing
Immunovant filed a proxy statement on July 22, 2026, providing details for shareholder voting and corporate governance matters.
Immunovant Proxy statement: Proxy filing
Immunovant filed a proxy statement on July 22, 2026, providing details for shareholder voting and corporate governance matters.
Immunovant price target raised to $61 from $57 at Citi
Citi raised the firm’s price target on Immunovant (IMVT) to $61 from $57 and keeps a Buy rating on the shares.
Immunovant price target raised to $47 from $35 at JPMorgan
JPMorgan raised the firm’s price target on Immunovant (IMVT) to $47 from $35 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q1…
Immunovant price target raised to $62 from $44 at Guggenheim
Guggenheim raised the firm’s price target on Immunovant (IMVT) to $62 from $44 and keeps a Buy rating on the shares. The firm updated its model after recent fiscal Q4…
Immunovant price target raised to $30 from $23 at Truist
Truist analyst Danielle Brill raised the firm’s price target on Immunovant (IMVT) to $30 from $23 and keeps a Hold rating on the shares. The firm is updating its model…
Immunovant price target raised to $43 from $32 at BofA
BofA analyst Jason Gerberry raised the firm’s price target on Immunovant (IMVT) to $43 from $32 and keeps a Buy rating on the shares, citing a higher peak sales outlook…
Immunovant price target raised to $40 from $35 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Immunovant (IMVT) to $40 from $35 and keeps a Buy rating on the shares. The firm says IMVT-1402 showed “robust responses” in…
This Is Why Immunovant Stock (IMVT) Is Up Today
Immunovant stock was up on Wednesday alongside an earnings update.
2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug
Immunovant reports clinically meaningful trial results for its lead drug candidate. That's good news for Roivant Sciences.
Immunovant Earnings Call Transcript: Q4 2026
Strong clinical and commercial progress highlighted by robust D2T RA data, rapid program execution, and a solid cash position. Key launches and data readouts are expected in the coming year, with significant momentum across the portfolio.
Immunovant Earnings release: Q4 2026
Immunovant released its Q4 2026 earnings on May 20, 2026, summarizing the period's financial results.
Immunovant Annual report: Q4 2026
Immunovant has published its Q4 2026 annual report on May 20, 2026.
Immunovant reports Q4 EPS (73c), consensus (63)
As of March 31, Immunovant’s (IMVT) cash and cash equivalents totaled approximately $902.1M, providing runway for announced indications through the potential commercial launch of IMVT-1402 in GD. Publ...
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026
DURHAM, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today report...
Immunovant Slides: Corporate presentation
Immunovant has posted slides in relation to its latest quarterly earnings report, which was published on May 20, 2026.
Immunovant price target raised to $32 from $29 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Immunovant (IMVT) to $32 from $29 and keeps a Neutral rating on the shares.
Immunovant price target lowered to $50 from $52 at Leerink
Leerink analyst Thomas Smith lowered the firm’s price target on Immunovant (IMVT) to $50 from $52 and keeps an Outperform rating on the shares. The firm notes the company reported…
Morning Movers: Immunovant sinks after batoclimab trials miss goal
Stock futures are lower across the board, reversing the gains that kicked off the second quarter. Markets are giving back yesterday’s relief rally in a sharp sentiment reversal, as geopolitical…
Immunovant Transcript: Study result
Brepocitinib's program is expanding to include a pivotal phase IIb/III trial in lichen planopilaris, targeting a high unmet need population with a mechanism well-suited to the disease's biology. Meanwhile, batoclimab's phase III TED study failed its primary endpoint, but data support ongoing Graves' disease programs and highlight the importance of deep IgG suppression.
Immunovant Press release: Study result
Immunovant issued a press release on April 2, 2026, disclosing material business information to investors.
Immunovant Slides: Study result
Immunovant has posted slides in relation to its latest quarterly earnings report, which was published on April 2, 2026.
Immunovant reports batoclimab clinical studies missed primary endpoint
Immunovant (IMVT) reported the topline results from its two Phase 3 clinical studies evaluating batoclimab as an investigational treatment for adults with active, moderate-to-severe thyroid eye diseas...